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Abstract
Equine type 1 polysaccharide storage myopathy (PSSM1), a common glycogenosis associated with an R309H founder
mutation in the glycogen synthase 1 gene (GYS1), shares pathological features with several human myopathies. In common
with related human disorders, the pathogenesis remains unclear in particular, the marked phenotypic variability between
affected animals. Given that affected animals accumulate glycogen and alpha-crystalline polysaccharide within their
muscles, it is possible that physical disruption associated with the presence of this material could exacerbate the
phenotype. The aim of this study was to compare the histopathological changes in horses with PSSM1, and specifically, to
investigate the hypothesis that the severity of underlying pathology, (e.g. vacuolation and inclusion formation) would (1) be
higher in homozygotes than heterozygotes and (2) correlate with clinical severity. Resting and post-exercise plasma creatine
kinase (CK) and aspartate aminotransferase (AST) enzyme activity measurements and muscle pathology were assessed in
matched cohorts of PSSM1 homozygotes, heterozygotes or control horses. Median (interquartile range (IR)) resting CK
activities were 364 (332–764) U/L for homozygotes, 301 (222–377) U/L for heterozygotes and 260 (216–320) U/L for controls,
and mean (+/2 SD) AST activity for homozygotes were 502 (+/116) U/L, for heterozygotes, 357 (+/292) U/L and for controls,
311 (+/264) U/L and were significantly different between groups (P = 0.04 and P= 0.01 respectively). Resting plasma AST
activity was significantly associated with the severity of subsarcolemmal vacuolation (rho = 0.816; P = 0.01) and cytoplasmic
inclusions (rho = 0.766; P = 0.01). There were fewer type 26 and more type 2a muscle fibres in PSSM1-affected horses. Our
results indicate that PSSM1 has incomplete dominance. Furthermore, the association between plasma muscle enzyme
activity and severity of underlying pathology suggests that physical disruption of myofibres may contribute to the
myopathic phenotype. This work provides insight into PSSM1 pathogenesis and has implications for related human
glycogenoses.
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Introduction
There are eleven glycogen storage myopathies recognized in
humans, associated with the excessive accumulation of glycogen
and/or amylopectin-like polyglucosan bodies within skeletal
muscle fibres [1]. In addition, reports exist of other human cases
with similar pathological features, where genetic causes are
suspected, but unknown [2]. To date, the pathophysiology of
many of these glycogenoses remains poorly understood. Patients
may develop muscle cramps, weakness, exercise intolerance and
rhabdomyolysis [3], but it remains unclear the degree to which
these signs are associated with the physical disruption of muscle
fibre ultrastructure by the accumulations of glycogen or poly-
glucosan [4], or with other disease mechanisms, such as
diminished energy supply [5,6,7].
Type 1 equine polysaccharide storage myopathy (PSSM1) in
horses is associated with a variety of clinical signs, including
intermittent exertional rhabdomyolysis, muscle fasciculations,
muscle atrophy, gait abnormalities and paresis [8]. PSSM1 was
first described in detail by Valberg and colleagues in 1992 [9] and
is associated with an autosomal dominant, missense, gain of
function mutation (R309H) in the skeletal muscle glycogen
synthase gene (GYS1) [10]. Suspected to be the result of an
ancestral founder, the identical mutation is found in many
different horse breeds worldwide, with some breeds, for example
Percheron and Belgian Draft horses, having a particularly high
disease prevalence [10,11,12]. As with some of the known human
glycogenoses [13,14,15,16], affected horses accumulate excessive
glycogen and abnormal alpha-crystalline polysaccharide inclusions
within skeletal muscle fibres, often in sub-sarcolemmal vacuoles or
cytoplasmic inclusions [17,18]. Consequently, study of this equine
disease may provide important information regarding the patho-
genesis of related human disorders, perhaps prompting novel
treatment or management strategies.
In PSSM1-affected horses, pathological changes are most
prominent in muscles with a high proportion of glycolytic (type
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26) fibres [19]. In addition to the non-specific, chronic myopathic
changes (internalised nuclei and increased fibre size variation),
affected horses accumulate glycogen and develop subsarcolemmal
vacuolation and granular cytoplasmic polysaccharide inclusions, as
they age [8,9,20,21]. Fibres containing polysaccharide inclusions
are often detected in clusters at the perimysium and epimysium
[20,22] perhaps due to regional differences in muscle fibre
metabolism and/or in nutrient provision and blood supply.
Typically, the inclusions consist of non-lysosomal bound intracy-
toplasmic aggregates of b particles of glycogen and polyglucosan
bodies composed of less highly branched glycogen, interspersed
with protein aggregates containing myoglobin, desmin and
ubiquitin [8,23].
Enhancing our understanding of the pathophysiology of this
equine disease may provide further insight into the role of
glycogen storage and polysaccharide inclusions in human glyco-
genoses; furthermore the high disease prevalence in horses [12]
may facilitate such investigations. It remains unclear whether
muscle cell damage in affected horses occurs as a result of an
underlying metabolic defect (with polysaccharide inclusions being
a co-incidental disease marker), or whether (and as in a murine
model of Pompe disease [24]), it relates to underlying structural
damage or myofibrillar dysfunction associated with the inclusions
(or both). Given the subsarcolemmal location of the polysaccharide
containing vacuoles in PSSM1, disruption of the dystrophin
associated glycoprotein complex (DAGC), or its interaction with
desmin and other sarcoplasmic intermediate filaments is plausible
[17]. Alternatively the pathogenesis may relate to reduced energy
substrate availability in the skeletal muscle of affected horses:
although no differences in the activity of the cellular energy sensor,
AMP-activated protein kinase, or in ATP or AMP concentrations,
were found in affected horses [25,26], increased inosine mono-
phosphate concentration supports a role for disturbed energy
metabolism [26], which could account for descriptions of
myopathies in young foals with the disorder [21,27].
As the clinical signs, and specifically the incidence of exertional
rhabdomyolysis, vary between horses with PSSM1 [8], other
factors must modify an individual animal’s phenotype. For
example, disease severity in PSSM1-affected horses increases in
animals that also harbor a ryanodine receptor (RYR1) mutation
[28]. Furthermore, the high prevalence of the R309H mutation
within certain breeds means that homozygotes are commonly
encountered; it is conceivable that some phenotypic variation may
depend on allele copy number, with the disorder having
incomplete dominance. Additional variation in phenotype may
in part, result from differences in the degree to which breeds rely
on oxidative and glycolytic muscle metabolism and specifically the
different fibre type composition between breeds and animals. In
one study of Quarter Horses with PSSM1, affected horses had 8%
more type 2a fibres and 8% fewer type 26 fibres than controls
[22]. This is in contrast to a subsequent study by the same group
looking at Belgian horses with PSSM, where no difference in fibre
type distribution between affected and control horses was found
[29]. Furthermore, as dietary and exercise manipulation form the
main stay of management recommendations for affected horses
[30], it is also likely that environmental factors influence the
disease phenotype.
Further investigation of skeletal muscle pathology in PSSM1
may help elucidate the mechanism by which the GYS1 mutation
results in the clinical signs, which in turn, may help direct novel
treatments and disease management. The variable skeletal muscle
phenotype in equine PSSM1 can be assessed by measurement of
serum muscle enzyme activities and through skeletal muscle
biopsy. In this manuscript we aimed to investigate the hypothesis
that the severity of skeletal muscle pathology in PSSM1 would be
greater in homozygotes than heterozygotes and controls. Further-
more, we hypothesised that horses with a higher proportion of
polysaccharide-containing fibres, vacuolation or inclusions, would
have higher resting, and/or post-exercise muscle enzyme activities.
Specifically, we aimed to compare the proportions of fibres
containing internalized nuclei, subsarcolemmal vacuoles and
cytoplasmic polysaccharide inclusions in skeletal muscle between
horses that were homozygous and heterozygous for the GYS1
mutation, and control horses. Secondly, we aimed to compare
fibre type composition between the different genotyped groups
and to examine the integrity of dystrophin labeling adjacent to the
subsarcolemmal vacuoles. Furthermore, given that some research-
ers have suggested a possible link between oxidant damage and
exertional rhabdomyolysis in horses [31] we compared plasma
vitamin E concentration between the groups.
Materials and Methods
All studies were approved by Auburn University’s
Institutional Animal Care and Use Committee (IACUC
2009-1536)
One hundred and twenty five Belgian and Percheron horses
maintained with identical management (24 hour turn out) and
diet, and owned by an Auburn University research facility, were
genotyped (with owner permission). In brief, DNA was extracted
from whole blood in EDTA using Nucleon’s BACC kit1 according
to the manufacturer’s instructions. Genotyping was performed via
a restriction fragment length polymorphism assay that identifies
horses as homozygous (H/H), heterozygous (H/R) or wild type
(R/R) for the GYS1 R309H mutation [10]. Of the 125 horses,
there were 9 homozygotes (H/H), 45 heterozygotes (H/R) and 71
unaffected animals (R/R). Three breed-, age- and sex-matched
cohorts of 8 animals of each genotype (24 in total) were identified
from these animals. All horses were not in current work, had 24-
hour pasture turn out and were fed 2 kg per day of a
supplementary concentrate diet and alfalfa as forage. The
concentrate diet was designed to provide 22 MJ per day per
horse, and contained 149 g/kg crude protein, 45 g/kg fat, 143 g/
kg fibre and 165 g/kg starch.
Medical records, that included bi-annual routine biochemical
analyses performed in January and July of each year from
December 2003 to July 2009, were available for all 24 study
horses. The number of available analyses depended on the time
each animal had been within the herd from 5 to 14 samples
(median of 9 samples). All resting serum creatine kinase (CK) and
aspartate transferase (AST) activities were recorded and the
median value calculated for each individual.
In order to measure resting muscle enzyme activity on the day
of biopsy (see below), additional venous blood samples were
collected by direct jugular venipuncture into heparinised and plain
Vacutainers2 from the horses in each genotyped cohort. In
addition, 4 horses (again matched for age and sex) from each
genotype performed a standard exercise test consisting of
20 minutes of submaximal exercise (trot and canter work). Blood
was collected immediately prior to, 4 and 24 hours post-exercise.
All blood samples were immediately centrifuged at 4uC, and serum
and heparinised plasma separated and stored at 280uC. Plasma
vitamin E concentrations were analysed by a commercial
laboratory (Veterinary Laboratories Agency, Shrewsbury, UK)
by reverse phase HPLC and detected using a Shimadzu RF 5513
spectrofluorometric detector. Serum CK and AST activity were
measured using a Roche Cobas C311 analyser4.
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Biopsy procedure
Four homozygotes, 8 heterozygotes and 6 control horses from
the matched cohorts were available for open muscle biopsy. While
standing under sedation, (combined detomidine and butorphanol)
and mepivicaine subcutaneous local anaesthesia, a
3 cm61 cm61 cm sample of semimembranosus muscle was
biopsied. Muscle was trimmed and immediately mounted onto a
cork disc, with the fibres orientated vertically, and snap frozen in
isopentane that had been pre-cooled in liquid nitrogen. These
samples were transported on dry ice and subsequently stored at
280uC.
Histopathology and immunohistochemistry
Fresh-frozen biopsy samples were sectioned at 8 and 16 mm,
using a cryostat and stored at 280uC. Subsequently, sections were
thawed, air dried for 20 minutes and then stained with haema-
toxylin and eosin (8 mm) and periodic acid Schiff (16 mm) with and
without prior digestion with amylase [32]. A minimum of 200
fibres were examined in randomly-acquired images, captured with
a 620 objective, using an Olympus BX41 microscope with
Micropublisher 3.3RTV Digital Camera (Qimaging). Haematox-
ylin and eosin-stained sections were evaluated to determine the
percentage of fibres containing subsarcolemmal vacuoles, poly-
saccharide accumulations not associated with the sarcolemma, and
internalised nuclei. The percentage of fibres containing diastase-
resistant polysaccharide was determined in the periodic acid Schiff
stained sections that had been pre-digested with diastase. The fibre
type of affected fibres was identified by comparing serial sections
stained, immunohistochemically for myosin heavy chains (below).
To characterise the fibre type muscle profiles, primary mouse
anti-fast myosin heavy chain type 2a antibody (A4.745; dilution 1:5
in phosphate buffered saline (PBS)) or anti-slow myosin heavy
chain antibody (MAB 16286; dilution 1:50 in PBS) were applied to
8 mm sections for 1 hour, to identify type 2a and type 1 muscle
fibres respectively [33]. In addition, both antibodies were applied
simultaneously to additional serial sections leaving type 26 fibres
unstained. To characterise dystrophin expression and localisation,
sections were incubated with mouse anti-DYS-2 antibody7
(dilution 1:20 in PBS) for 1 hour. Biotinylated anti-mouse
antibody1 (dilution 1: 200 in PBS) was applied secondarily
followed by a tertiary peroxidase–streptavidin conjugate8 (dilution
1:500 in PBS), both for 1 hour. A chromagenic substrate
(Vectastain9) was then applied for 5 minutes followed by
counterstaining with Gill’s haematoxylin for 1 minute. Serial
images stained for each fibre type were captured from randomly-
selected areas using a610 objective and a minimum of 450 fibres
were identified and typed.
Statistical analysis
The normally distributed (Kolmogorov Smirnov test) age, breed
and sex distribution data within groups were compared by one
way analysis of variance (ANOVA) and chi square tests to confirm
appropriate matching of groups. Subsequently, one-way ANOVA
or Kruskal Wallis tests were used to compare data between
genotyped groups following testing for normality. Where suitable,
data that was not normally distributed was transformed prior to
analysis. Post-hoc analysis included the use of Mann Whitney tests
with Bonferroni correction. Associations between histopathological
changes and muscle enzyme activities were assessed using
Pearson’s correlation coefficients or Spearman’s correlation
coefficients for normally, or non-normally distributed data
respectively. All analyses were performed using statistical soft-
ware10 and differences were considered statistically significant
when P#0.05.
Results
Signalment
There was no difference between the age, breed or sex of the
three genotyped groups for either part of this study. Signalment
data is presented in table 1. None of the horses included in this
study had a history of muscle pain, cramping, sweating or exercise
intolerance.
Histopathology and immunohistochemistry
A trend towards a higher percentage of muscle fibres containing
internalised nuclei in the homozygous and heterozygous horses
was observed when compared to the control horses and the
difference between the 3 groups approached significance (p= 0.07)
(figure 1a). A greater proportion of muscle fibres contained
subsarcolemmal vacuoles (p,0.01) (figure 1b), cytoplasmic inclu-
sions (p,0.01) (figure 1c) and diastase-resistant inclusions (p,0.01)
(figure 1d) in the homozygous horses, when compared with the
heterozygous and control groups. Following post-hoc analysis,
significant differences between the homozygote and heterozygote
groups were not identified for the percentage of fibres containing
cytoplasmic inclusions (p = 0.15) or the percentage of fibres
containing subsarcolemmal inclusions (p = 0.12), however the
homozygotes had more fibres containing amylase-resistant inclu-
sions (p = 0.05). There was a marked and significant correlation
Table 1. Signalment of all horses participating in each section of the study, showing no significant differences between matched
groups.
Part of study Genotype Age P-value Male Female P-value Percheron Belgian P-Value
24 Horses HH n= 8 9.6 (2.6) 0.99 5 3 0.47 3 5 0.11
HR n= 8 9.8 (2.4) 3 5 1 7
RR n = 8 9.9 (2.7) 3 5 3 5
Biopsy horses HH n= 4 9.2 (3.4) 0.99 2 2 0.28 2 2 0.10
HR n= 8 9.6 (2.4) 4 4 2 6
RR n = 6 9.7 (2.9) 3 3 2 4
Exercise test HH n= 4 9.3 (1.9) 0.98 2 2 0.56 2 2 0.56
HR n= 4 9.5 (2.4) 1 3 1 3
RR n = 4 9.3 (1.9) 2 2 1 3
doi:10.1371/journal.pone.0042317.t001
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between the presence of subsarcolemmal vacuoles (rho= 0.86;
p,0.001), and cytoplasmic inclusions (rho= 0.83; p,0.001), and
the number of mutant alleles, and moderate, but significant
correlation between the proportion of internalized nuclei and the
number of mutant alleles (rho= 0.56; p = 0.02). Normal dystro-
phin localization and expression was identified at the sarcolemma
in all muscle fibres, with no apparent reduction in expression
adjacent to regions of subsarcolemmal vacuolation in either
heterozygotes or homozygotes (figure 2).
Fibre types
There was no difference in the proportion of type 1 fibres within
skeletal muscle (p = 0.06), between the 3 groups, however there
was a significant difference between the proportion of type 2a
(p = 0.04) and type 26 fibres (p = 0.03) within the muscle samples.
Figure 1. The effect of GYS1 genotype on skeletal muscle histopathology. a–d: Boxplots illustrating the percentage of muscle fibres
containing (a) internalised nuclei, (b) subsarcolemmal vacuoles, (c) cytoplasmic inclusions and (d) diastase resistant inclusions in horses homozygous
(HH) and heterozygous (HR) for GYS1 mutation and controls (RR). * Denotes significant differences between individual groups (p,0.05), ** (p,0.01),
following post- hoc analysis. e–h: Representative images of the pathology (arrows) identified (e) internalized nuclei, (f) subsarcolemmal vacuoles, (g)
cytoplasmic inclusions and (h) diastase resistant inclusions (e–g: haematoxylin and eosin; h: Periodic acid Schiff following diastase digestion).
Bar = 50 mm.
doi:10.1371/journal.pone.0042317.g001
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Homozygotes had significantly more type 2a fibres than hetero-
zygotes (p = 0.02) and controls (p = 0.03) and significantly fewer
type 26 fibres than controls (p,0.05) (figure 3). There was no
difference in the proportion of type 1 (p= 0.67) (HH medi-
an = 4.5%; (interquartile range (IR): 1.9–40.2); HR=1.93% (0.4–
4.91) RR=0.01% (0–0.01)) or type 26 fibres (p = 0.20) (HH
median= 10.6%; (interquartile range (IR): 4.9–17.3); HR=15.2%
(4.8–18.3) RR=0.00% (0–0.4)) containing polysaccharide inclu-
sions, however muscle from homozygous horses contained a
significantly greater percentage of diastase-resistant polysaccha-
ride-containing type 2a fibres (p =,0.0001) (HH medi-
an = 29.5%; (interquartile range (IR): 20.3–41.7); HR=9.4%
(4.5–15.0) RR=0.00% (0–0.07)) than the other genotyped groups.
Muscle enzyme activities
There was a significant difference between the groups’ resting
serum muscle enzyme activities (CK; p= 0.04 and AST; p= 0.01),
with higher activities observed in homozygotes, followed by
heterozygotes, in comparison with the control horses (Figure 4).
There was a significant difference between CK activities at
4 hours post-exercise (p = 0.04) between the groups, with homo-
zygotes having significantly higher activities (p,0.05) than control
horses after post hoc analysis: this difference between genotypes also
approached significance at 24 hours post exercise (p = 0.06)
(Figure 5). There was no significant difference between heterozy-
gous and control horses; indeed, there was considerable overlap
between the two groups. When all horses with PSSM1 were
combined (heterozygotes and homozygotes) and compared to
control horses, a significant difference was detected in CK activity
at 4 hours (p = 0.02) (PSSM1 median = 965 U/L (interquartile
range (IR) 428–1989); RR=253 U/L (IR 180–311)) but not
24 hours post-exercise (p = 0.07) (PSSM1 median = 1039 U/L (IR
360–2424); RR=250 U/L (IR 161–528)). No difference in post-
exercise AST activity was detected between the three groups at
4 hours post-exercise (p = 0.20) or 24 hours after exercise
(p = 0.17) (figure 5), neither were there significant differences in
AST activity after exercise in a combined PSSM1 heterozygote
and homozygote group compared with controls (4 hours post-
exercise; p = 0.22 (PSSM1 median= 422 U/L (IR 295–650);
RR=280 U/L (IR 235–494)); 24 hours post exercise; p = 0.46
(PSSM1 median = 478 U/L (IR 280–713); RR=325 U/L (IR
263–528))). For all horses, there was a significant correlation
between pre-exercise CK activity and that at 4 (rho= 0.68;
p = 0.01) and 24 hours (rho= 0.77; p,0.01) post-exercise, and
between pre-exercise AST activity and that at 4 (r2 = 0.97;
p,0.001) and 24 (r2 = 0.52; p,0.01) hours post-exercise.
There was a strong and significant association between the
resting serum AST activity and the percentage of fibres with
sarcoplasmic vacuoles (rho= 0.82; p= 0.01) and cytoplasmic
inclusions (rho= 0.77; p = 0.01), but not internalised nuclei
(rho= 0.44; p= 0.08) (figure 6), and a moderate but significant
association between resting CK activity and subsarcolemmal
vacuoles (rho= 0.51; p = 0.03), cytoplasmic inclusions (rho= 0.48;
p = 0.05) and internalised nuclei (rho= 0.50; p = 0.04).
Vitamin E
There was no difference between the plasma vitamin E
concentrations of horses that were homozygous or heterozygous
for the GYS1 mutation or the control horses (p = 0.80), though
Figure 2. Dystrophin localisation. Representative images of
dystrophin immunohistochemistry (brown staining) in skeletal muscle
counterstained with haematoxylin and eosin from (A) a control horse
and (B) a horse heterozygous for the GYS1 mutation. Note the normal
dystrophin expression and localisation in the region of the subsarco-
lemmal vacuoles (arrows). Bar = 50 mm.
doi:10.1371/journal.pone.0042317.g002
Figure 3. Muscle fibre type distributions. Boxplots illustrating the
muscle fibre type composition of horses homozygous (HH) (n = 4),
heterozygous (HR) (n = 8) and control horses (RR) (n = 6). * Denotes
significant differences between individual groups (p,0.05) following
post- hoc analysis.
doi:10.1371/journal.pone.0042317.g003
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control horses had higher vitamin E concentrations (mean +/2SD
9.86 mmol/l+/21.92 (normal .4)) than the heterozygotes
(9.10 mmol/l+/22.44), which in turn had higher concentrations
than homozygotes (8.96 mmol/l+/23.56).
Discussion
Equine PSSM1 manifests with a variety of clinical signs but the
reason for this phenotypic variation is not clearly understood. A
better understanding of the factors that act to modify the clinical
presentation may provide clues as to the pathophysiology of the
disease and ultimately aid in selecting appropriate treatment or
management strategies. With many related and poorly understood
glycogen storage diseases in humans [1], some findings may have
relevance to the related human field. We have shown that skeletal
muscle pathology in PSSM1 is typically more severe in homozy-
gotes than heterozygotes and that horses with a higher proportion
of polysaccharide-containing fibres and fibres with sub-sarcolem-
mal vacuolation have higher resting muscle enzyme activities.
This is the first study to demonstrate that the severity of muscle
histopathological changes in PSSM1 depends on the underlying
genotype and therefore supports the importance of genotyping
affected individuals. Subsarcolemmal vacuolation and fibres with
cytoplasmic inclusions were more prevalent in homozygotes than
heterozygotes and both homozygous and heterozygous horses had
more fibres containing internalised nuclei than control horses.
Homozygotes had more fibres containing amylase-resistant
polysaccharide inclusions than heterozygotes and in particular, a
higher proportion of the mixed glycolytic-oxidative type 2A fibres
containing amylase-resistant inclusions than heterozygotes. This
excessive accumulation of polysaccharide aggregates appears
directly related to increased activity of the mutant enzyme [10],
and formation of less highly branched molecule [17].
In equine PSSM1, similar to the many human skeletal muscle
glycogenoses, it is not yet understood how the presence of
excessive glycogen and polysaccharide inclusions relates to the
underlying disease. We found a strong and significant association
between serum muscle enzyme activities and the proportion of
fibres with polysaccharide aggregates and subsarcolemmal vacu-
oles. Although we cannot exclude the possibility that an underlying
and unknown metabolic defect results in both the elevation in
muscle enzyme activity and also the pathology independently, it
seems plausible that muscle enzyme activities are higher in animals
with more severe pathology because of physical disruption of the
myofibrillar apparatus. We demonstrated normal dystrophin
expression and normal sarcolemmal localisation adjacent to
subsarcolemmal vacuoles in horses at rest; however it is
conceivable that loss of interaction between the dystrophin-
associated complex and the myofibrillar apparatus leads to fibre
damage that is exacerbated by exercise (as seen in Duchenne
muscular dystrophy) [34]. Alternatively, presence of glycogen or
polysaccharide in itself may underlie the phenotype, as shown in
neurons with artificially-induced excessive glycogen storage [35].
Indeed, although young foals with PSSM1 have been described
(supporting a role for a metabolic defect), they also had higher
Figure 4. Resting muscle enzyme activities. Box plots illustrating
the resting (a) CK activity and (b) AST activity for each GYS1 genotype
(n = 8) (HH=homozygotes, HR=heterozygote, RR = control) * Denotes
significant differences between individual groups (p,0.05) following
post- hoc analysis.
doi:10.1371/journal.pone.0042317.g004
Figure 5. Pre- and post exercise muscle enzyme activites. Graph
illustrating the pre and post exercise (a) CK activity and (b) AST activity
for each GYS1 genotype (n = 4) (HH=homozygotes, HR= heterozygote,
RR = control).
doi:10.1371/journal.pone.0042317.g005
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muscle glycogen contents, sarcolemmal vacuolation and/or
amylase-resistant polysaccharide from an early age [21,27].
Perhaps regular and consistent exercise, which appear to be
protective in PSSM1-affected horses and foals [21,30] help
enhance glycogen mobilization with concomitantly a reduction
in vacuolation or cytoplasmic aggregation, and therefore less
propensity to result in exercise-associated structural damage. We
recently speculated that the constant work performed by the
contracting heart protects against a cardiomyopathy in PSSM1,
perhaps for the same reasons [36]. A future prospective study
comparing skeletal muscle pathology in exercised vs non-exercised
horses would be insightful.
In this study we demonstrated an association between the GYS1
genotype and post-exercise CK and AST activities. Although there
was a significant difference between the mean post-exercise CK
activity of each group, the ranges of muscle enzyme activity
overlap considerably, in particular between normal horses and
heterozygotes and in some affected animals, it remains within the
normal laboratory reference range both at rest and following
submaximal exercise. Although we evaluated relatively few horses,
resting or post-exercise muscle enzyme activity measurements
appear to have low sensitivity and specificity. Some previous
reports suggested muscle enzyme activity to be a useful screening
test for PSSM1 [26,37], however more recent work has
demonstrated that many horses that are heterozygous for the
GYS1 mutation do not reach the previously suggested cut-off levels
of 2–3 times resting muscle enzyme activity following exercise
[38], as was observed in our study. In contrast to the findings in
our study, Schwarz and co-workers [38] observed a significant
difference between resting and post exercise AST activities and
post exercise CK between heterozygous and control horses,
although their study did not evaluate homozygotes. Until these
discrepancies are better understood the genotyping of horses is
recommended, even in the absence of significant elevations in
post-exercise muscle enzyme activity, particularly in breeds with a
high prevalence of the mutant GYS1 allele.
Given the association between muscle enzyme activity and
underlying pathology, CK and AST activity measurement may
instead be useful prognostically for affected horses: the stronger
association between histopathology and resting AST rather than
CK activity supports the association of the pathology and chronic
muscle damage. It is surprising that none of the horses in this study
had shown clinical signs of muscle disease given the severity of the
histopathology observed. This may reflect the low level of work
performed by the horses included in this study or their permanent
turn-out, as regular low intensity exercise is protective [30]. We
suggest that horses that are worked hard may be more prone to
exercise-associated muscle damage and hence rhabdomyolysis.
In this study we identified significant differences in fibre type
proportions between the groups: horses with PSSM1 had a higher
percentage of type 2a and fewer type 26 fibres, than controls and
the extent of this difference was greatest for the homozygotes. This
change in fibre type may be a reflect a shift from glycolytic towards
more oxidative metabolism or be a consequence of type 26 fibre
loss in affected horses. These findings are similar to those of
Annandale and coworkers [22] who found 8% more type 2a fibres
and 8% fewer type 26 fibres in Quarter Horses with PSSM;
however, they contrast a subsequent study by the same group
looking at Belgian horses with PSSM, where no difference in fibre
type distribution between affected and control horses was found
[29]. A fibre type shift with an increased proportion of type 2a
fibres is an adaptive response to endurance training in human and
equine athletes [39,40,41] however the horses in this study were
not under training and were managed identically. The fibre type
shift in affected horses may be an adaptive response, away from
glycolytic and towards oxidative metabolism; in addition, the
protective effect of regular exercise in PSSM1-affected horses
would further encourage this adaptation [39,40,41]. Despite this,
polysaccharide inclusions were still encountered in the mixed
glycolytic-oxidative (2a) fibres, particularly in homozygotes. Given
the similarities between PSSM1 and several human myopathies,
further work to evaluate fibre type shifts (either induced or disease-
associated) in human patients with skeletal muscle glycogenoses
may be indicated.
Another possible mechanism of disease in glycogen storage
diseases is free radical damage secondary to normal electron
transfer, muscle inflammation or ischaemia [42]. Vitamin E is the
principal defense for reactive oxygen species in tissues and skeletal
muscle contains lower concentrations of vitamin E than other
body organs [43], and may be more vulnerable to free radical
damage, particularly in response to the large increases in
metabolic demand that occur at exercise [42]. As in a previous
study [44] we did not detect a significant difference between the
plasma vitamin E concentrations between the different genotyped
groups, however occasional homozygotes had plasma vitamin E
concentrations below the normal reference range suggesting the
possibility of excessive consumption. The lack of significance in
this study may reflect the relatively small sample sizes; the
potential beneficial effect of dietary supplementation with vitamin
E for individuals with skeletal muscle glycogenoses, including
horses with PSSM1 warrants further investigation.
Figure 6. The correlation between muscle enzyme activity and
muscle histopathology. Scattergraphs illustrating the correlation
between the Log10 resting CK activity (A) and Log10 AST activity (B) and
the percentage of fibres containing subsarcolemmal vacuoles.
(HH= triangles, HR= stars, RR = circles) (n = 18).
doi:10.1371/journal.pone.0042317.g006
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In this study we have demonstrated a correlation between
number of copies of the mutant GYS1 allele, the severity of skeletal
muscle pathology and the resting muscle enzyme activity. PSSM1
therefore has incomplete dominance and our work highlights the
importance of genotyping affected animals to identify those
individuals most likely to be more severely affected. Our work
supports the possibility that there is a direct link between myofibre
structural damage and the severity of the underlying phenotype.
Furthermore, it suggests that management and treatment strate-
gies aimed at maintenance of myofibre integrity may be beneficial
in affected horses. Given the many similarities between PSSM1
and several human skeletal muscle glycogenoses, further study of
this equine disorder may provide a useful model for work
investigating the pathophysiology of this group of poorly
understood, but important human diseases [45,46].
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